Acrivon Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for ACRV, updated each market day.
ACRV AI Sentiment
AI sees no strong directional signal for Acrivon Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
Sector
Exchange
Market Cap
$60,053,891
Cap Tier
Employees
76
Headquarters
WATERTOWN, MA
Listed Since
Nov. 15, 2022
Website
ACRV Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ACRV Volatility
Acrivon Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
